Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug safety comments

This article was originally published in The Tan Sheet

Executive Summary

FDA seeks comments on its draft drug safety five-year plan, according to a notice scheduled for publication in the May 5 Federal Register. The plan, released April 1, outlines how FDA will spend Prescription Drug User Fees, such as on hiring more safety inspectors for marketed medications and more staff to review mandatory post-approval studies, label changes and other risks (1"The Tan Sheet" April 14, 2008, p. 10). Comments are due in June...

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts